Welcome to our dedicated page for Bio Rad Labs SEC filings (Ticker: BIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digital PCR breakthroughs, global reagent supply chains, and multi-segment revenue streams make Bio-Rad Laboratories’ (BIO) SEC disclosures some of the most intricate in the life-science arena. Parsing a 300-page annual report to locate FDA clearance updates, or tracking when executives sell shares ahead of a new diagnostics launch, can drain hours. That complexity is exactly why users search for phrases like “Bio-Rad insider trading Form 4 transactions” or “How do I read a Bio-Rad annual report 10-K simplified?”
Stock Titan solves this problem with AI-powered analysis that translates legal jargon into plain English. Whether you need the “Bio-Rad quarterly earnings report 10-Q filing” or a sudden “Bio-Rad 8-K material events explained,” our platform delivers real-time alerts the moment documents hit EDGAR. Instantly skim AI summaries that highlight segment sales swings, R&D intensity, and patent litigation, then dive deeper using smart search to locate specific accounting notes. You’ll also receive live notifications for “Bio-Rad Form 4 insider transactions real-time,” so monitoring “Bio-Rad executive stock transactions Form 4” no longer requires constant manual checks.
Here’s how professionals use the page:
- Compare diagnostics vs life-science margins within the “Bio-Rad earnings report filing analysis.”
- Review director pay packages via the “Bio-Rad proxy statement executive compensation.”
- Stay ahead of product-launch risk factors using “understanding Bio-Rad SEC documents with AI.”
Every filing type—10-K, 10-Q, 8-K, Form 4, DEF 14A—is captured, indexed, and summarized. Complex filings explained simply; insights delivered instantly.
Rajat Mehta, Executive Vice President, Global Commercial Operations at Bio-Rad Laboratories, Inc. (BIO), reported grants of restricted stock units on 09/05/2025. The Form 4 shows two awards: 1,827 RSUs and 5,480 RSUs, each representing the contingent right to one share of Bio-Rad Class A common stock. Both grants have a $0 per-unit reported conversion price and are held directly by the reporting person. The 1,827 RSUs vest in four equal annual installments beginning on the first anniversary of the grant date; the 5,480 RSUs vest over four years at 25% per year on each annual anniversary. The filing is signed 09/09/2025.
Allison Schwartz, a director of Bio-Rad Laboratories (BIO), reported insider transactions on Form 4 covering September 1, 2025. The filing shows vesting-driven acquisitions: 147 shares of Class A common stock were added on vesting of restricted stock units at no cash cost and 31, 42, and 74 RSUs vested (representing rights to 31, 42 and 74 shares). Following the transactions, Ms. Schwartz beneficially owned 1,452 shares of Class A common stock directly. The report also discloses a sale of 55 shares at $297.88 each, reducing direct holdings to 1,397 shares. The filing reflects routine executive equity compensation and a small open-market sale.
Bio-Rad insider transaction summary: EVP and President, LSG Barry James reported transactions on 09/01/2025 involving Bio-Rad Laboratories Class A common stock (BIO). The filing shows 602 shares were acquired and added to his direct holdings following the vesting of restricted stock units, increasing his direct beneficial ownership to 748.555 shares. The filing also reports a disposition of 217 shares sold at $297.88 per share, leaving 531.555 shares after that sale. Separately, the report lists restricted stock unit activity: 178 units vested (converted to 0 shares remaining), 174 units vested and remain as 174 shares, and 250 units vested increasing total RSU-derived shares to 502. The transactions are documented on a Form 4 signed 09/02/2025.
Colleen Corey, Executive Vice President, Global Human Resources of Bio-Rad Laboratories, reported insider transactions dated 09/01/2025. The filing shows 1,102 shares of Bio-Rad Class A common stock were acquired on vesting of restricted stock units at no cash price, and 398 shares were disposed of at $297.88 per share. Following the transactions, the reporting person beneficially owned 19,581 shares after the vesting event and 19,183 shares after the sale, as shown in the form.
The filing also reports restricted stock unit activity: vesting-related entries of 254, 347, and 501 RSUs tied to prior grants from 2021, 2022, and 2023, with the explanatory note that each RSU represents a contingent right to one share.
Norman D. Schwartz, Chairman & CEO of Bio-Rad Laboratories (BIO), reported changes in his beneficial ownership on September 1, 2025. He acquired 6,353 Class A shares on vesting of restricted stock units and had 3,084 Class A shares disposed of at $297.88 per share. After these transactions he directly owned 444,591 Class A shares. The filing also reports direct ownership of 361,466 Class B shares and indirect holdings of 13,006 Class B shares (by spouse) and 4,060,054 Class B shares (by Blue Raven Partners, L.P.). Several restricted stock unit vesting events are noted, reflecting prior grants from 2021–2023 that vest in annual installments.
Rajat Mehta, listed as Executive Vice President, GBL Commercial Operations at Bio-Rad Laboratories (BIO), filed an initial Form 3 reporting the Section 16 beneficial-ownership status. The event date is 08/04/2025 and the form is signed 08/14/2025. The filing states no securities beneficially owned (0 shares) by the reporting person, with ownership shown as direct (D) where applicable.
FAQ
What is the current stock price of Bio Rad Labs (BIO)?
What is the market cap of Bio Rad Labs (BIO)?
